The MAPK pathway could provide such signalling (Gray‐Schopfer et al., 2007), and indeed, long‐term BRAF or MEK inhibitor treatment of melanoma cells can trigger melanogenesis (Haq et al., 2013a). Here, BRAF is linked to melanoma.